Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.785 USD | -2.46% | -2.19% | -87.84% |
Financials (USD)
Sales 2024 * | 97.16M | Sales 2025 * | - | Capitalization | 124M |
---|---|---|---|---|---|
Net income 2024 * | -206M | Net income 2025 * | -93M | EV / Sales 2024 * | 0.38 x |
Net cash position 2024 * | 87.38M | Net cash position 2025 * | 62.5M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.61
x | P/E ratio 2025 * |
-1.39
x | Employees | 384 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.34% |
Latest transcript on Amylyx Pharmaceuticals, Inc.
1 day | -2.46% | ||
1 week | -2.19% | ||
Current month | -1.10% | ||
1 month | -8.21% | ||
3 months | -89.86% | ||
6 months | -86.41% | ||
Current year | -87.84% |
Managers | Title | Age | Since |
---|---|---|---|
Justin Klee
FOU | Founder | 34 | 12-12-31 |
Josh Cohen
FOU | Founder | 33 | 12-12-31 |
Jim Frates
DFI | Director of Finance/CFO | 56 | 20-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
George Milne
CHM | Chairman | 80 | 14-12-31 |
Kari Firestone
BRD | Director/Board Member | - | 23-03-15 |
Paul R. Fonteyne
BRD | Director/Board Member | 63 | 21-03-28 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.14% | 0 M€ | 0.00% | - | |
0.09% | 234 M€ | +8.48% | - | |
0.04% | 2 M€ | -.--% | ||
0.02% | 9 M€ | +10.49% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-23 | 1.79 | -2.19% | 171 500 |
24-05-22 | 1.83 | +1.67% | 687,162 |
24-05-21 | 1.8 | -2.17% | 895,387 |
24-05-20 | 1.84 | +0.55% | 1,168,847 |
24-05-17 | 1.83 | 0.00% | 1,222,822 |
Delayed Quote Nasdaq, May 23, 2024 at 10:42 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-87.84% | 124M | |
-1.62% | 89.22B | |
+2.24% | 40.49B | |
-15.16% | 32.79B | |
+63.50% | 26.23B | |
-21.88% | 14.52B | |
-7.80% | 13.09B | |
-42.60% | 11.6B | |
-12.64% | 11.5B | |
+5.24% | 8.82B |
- Stock Market
- Equities
- AMLX Stock